Premium
Premium statistics

Industry-specific and extensively researched technical data (partially from exclusive partnerships).

A paid subscription is required for full access.

Proportion of branded versus generic prescription drug revenues in the United States from 2005 to 2016

Exclusive Premium Statistic

U.S. brand and generic prescription drug revenue 2005-2016 This statistic compares brand drug prescription revenues of branded and unbranded generics in the United States from 2005 to 2015. In 2005, some 81 percent of total U.S. prescription revenues were made through brand name medications. However, this share decreased to some 71 percent in 2013, and increased slightly to over 74 percent in 2016. Generics are copies or equivalents of once patent protected drugs, containing the same active ingredient, in the same amount, in the same form, dissolving at the same rate in equal amounts like the original.
Show more
BrandsBranded GenericsUnbranded Generics
----
----
----
----
----
----
----
----
----
----
----
----
BrandsBranded GenericsUnbranded Generics
----
----
----
----
----
----
----
----
----
----
----
----

Exclusive Premium statistic

You need a Premium Account for unlimited access.

  • Full access to 1.5m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Premium Account


only $49 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$588 / Year

View price details

Exclusive Premium statistic

You need a Premium Account for unlimited access.

  • Full access to 1.5m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Premium Account


only $49 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$588 / Year

View price details

Download Settings Share
Chart type
Datalabels
Share on Social Media
Download started
Please be patient - this may take a moment
Description Source More information
This statistic compares brand drug prescription revenues of branded and unbranded generics in the United States from 2005 to 2015. In 2005, some 81 percent of total U.S. prescription revenues were made through brand name medications. However, this share decreased to some 71 percent in 2013, and increased slightly to over 74 percent in 2016. Generics are copies or equivalents of once patent protected drugs, containing the same active ingredient, in the same amount, in the same form, dissolving at the same rate in equal amounts like the original.
Show more
Release date
May 2017
Region
United States
Survey time period
2005 to 2016
Supplementary notes
Report reflects prescription-bound products including insulins and excluding other products such as OTC. Includes prescriptions and insulins dispensed by chain and independent pharmacies, food store pharmacies, mail service pharmacies, and long-term care facilities. Spending figures also include sales into hospitals, clinics, and other institutional settings. Prescription counts are not adjusted for length of therapy. 90-day and 30-day prescriptions are both counted as one prescription.
This statistic was assembled from several IMS Health/QuintilesIMS reports.

More information

Statista Accounts: Access All Statistics. Starting from $588 / Year

Basic Account

Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Premium Account

Your perfect start with Statista

  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$49 / Month *

Corporate Account

Full access

Corporate solution including all features.

Send request

* All products require an annual contract.
   Prices do not include sales tax
   (New York residents only).
Leading companies trust Statista:
paypalgoogleadobepgsamsungtelekom

Related Studies: Available to Download in PDF or PPTX Format

Generics and biosimilars
Generics and biosimilars

All Information
in one Presentation

Generics and biosimilars

Everything On "Generics and biosimilars" in One Document: Edited and Divided into Handy Chapters. Including Detailed References.

Other Reports & Dossiers
Statista is a great source of knowledge, and pretty helpful to manage the daily work.
Christof Baron

Christof Baron
CEO, MindShare Germany

Statistics on "Generics and biosimilars"

  • Global overview
  • Top companies
  • U.S. market
The most important statistics
  • Patent expiration
  • Savings
  • Biosimilars
Need help with using Statista for your research? Tutorials and first steps

Further Content: Statistics, Studies, and Topic Pages

Statistics on the topic

Topics

About Statista

Learn more about how Statista can support your business.

Request webinar
Do you have any questions about our business solutions?

We provide you with detailed information about our Corporate Account.